From Biology to Breakthroughs in Obesity Therapeutics (R6)
January 1-5, 2028
| Location to be Determined
Saturday, January 1, 2028
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
| 8:00–8:10 AM |
Welcome Remarks |
|
| 8:10–9:00 AM |
Keynote Address |
|
| |
Ruth E. Gimeno †, Eli Lilly and Company
From Biology to Breakthroughs in Obesity Therapeutics |
|
| 9:00–11:15 AM |
Basic Biology of Incretin- and Amylin-Based Therapeutics |
|
| |
Matthias H. Tschöp †, Ludwig-Maximilians-Universität München (LMU)
Multi-Receptor Potential of Incretin Therapies: Basic Biology of Obesity Therapeutics |
|
| |
Thomas A Lutz †, University of Zürich
Biology of Amylin Receptor Agonists |
|
| |
Manu Chakravarthy †, Roche
Current Status and Potential of Incretin & Amylin-based Obesity Therapies |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:25–12:25 PM |
Panel Discussion: Translation of Obesity Human Genetics |
|
| |
* Kendra K Bence, Eli Lilly and Company
|
|
| 12:25–1:00 PM |
Poster Setup |
|
| 12:25–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Obesity Drug Discovery at the Edge: Novel Targets, Mechanisms & Modalities |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
GLP1 Therapies Beyond Weight Loss: Cardiometabolic Protection and Addiction |
|
| |
Daniel J. Drucker †, Lunenfeld-Tanenbaum Research Institute
Expanding Therapeutic Roles for GLP1-R Agonists Beyond Weight Loss: Cardiometabolic Protection |
|
| |
Ian Neeland †, Case Western Reserve University
Weight Loss Quality and Cardiovascular Risk |
|
| |
Ali Guler †, University of Virginia
GLP1 Therapies and Addiction/Reward |
|
| |
Anna Secher, Novo Nordisk A/S
CNS Mechanisms of GLP1R Agonists (Cognition?) |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Neural Circuits Underlying Energy Balance and Appetite Control |
|
| |
Matthew R. Hayes, University of Pennsylvania
Neural Circuits of Appetite Control: Convergence of Gut and Brain |
|
| |
Amber L. Alhadeff †, Monell Chemical Senses Center
Dissociable Neural Circuits for Satiety and Nausea in the Control of Feeding |
|
| |
Martin G. Myers, Jr. †, University of Michigan
Neuroendocrine Circuits Regulating Body Weight: Implications for Obesity |
|
| |
Alice E Adriaenssens †, AstraZeneca
Central Incretin Circuits: How GIP and GLP 1 Shape Feeding and Obesity |
|
| |
Alastair Garfield †, Rhythm Pharmaceuticals
MC4R Pathways and Hypothalamic Obesity |
|
| |
Mark W. Sleeman †, Regeneron Pharmaceuticals
GPR75: Challenges and Progress in Novel Obesity Genetic Targets |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Energy Expenditure and Metabolic Efficiency |
|
| |
E. Matthew Morris †, University of Kansas Medical Center
Metabolic Adaptation and Energy Expenditure in Obesity |
|
| |
Kristy Townsend †, The Ohio State University
Adipose Innervation as a Driver of Energy Expenditure in Obesity |
|
| |
Gerald I Shulman †, Yale School of Medicine
Ectopic Lipid, Mitochondrial Inefficiency, and the Regulation of Energy Expenditure in Obesity |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Adipose Tissue Function and Obesogenic Memory |
|
| |
Susanne Mandrup †, University of Southern Denmark
Human Adipose Remodeling |
|
| |
Paul Cohen †, Rockefeller University
Rewiring Adipose Tissue for Metabolic Health |
|
| |
Anthony W Ferrante †, Columbia University
Immune–Adipocyte Crosstalk and the Encoding of Obesogenic Memory |
|
| |
Christian Wolfrum †, Nanyang Technical University
Adipose Tissue Heterogeneity, Plasticity, and Memory: Implications for Metabolic Health |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2 |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Optimizing Body Composition: Muscle Function and Sarcopenia |
|
| |
Andreas L Birkenfeld †, Helmholtz Munich and Universitätsklinikum Tübingen
Weight Loss Quality and Clinically Important Outcomes Beyond BMI |
|
| |
Dympna Gallagher †, Columbia University
Beyond BMI: Quantifying Skeletal Muscle and Body Composition in Obesity |
|
| |
Paul M. Titchenell †, Eli Lilly
Optimizing the Fat–Muscle Equation: New Therapeutic Strategies in Obesity |
|
| |
Danna M. Breen †, Pfizer Inc.
Muscle on the Spectrum: Obese Sarcopenia to Cachexia |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
Wednesday, January 5, 2028
